Beal Margaret W, Simmonds Kathy
Yale University School of Nursing, New Haven, CT 06536-0740, USA.
J Midwifery Womens Health. 2002 Nov-Dec;47(6):451-60. doi: 10.1016/s1526-9523(02)00331-8.
In September 2000, the U.S. Food and Drug Administration (FDA) approved the use of mifepristone for the provision of medical abortion. Although mifepristone was developed and marketed because of its potential to effect early first-trimester medical abortion, it has additional applications to health care, including the treatment of gynecologic conditions, cancer, and Cushing's disease. The controversial nature of abortion has dominated the publicity about mifepristone. The evidence for the safety and efficacy of mifepristone in medical abortion has been overshadowed, and many clinicians are unaware of the other potential uses of the drug. This article provides a discussion of background information on the pharmacology, development of, and research on mifepristone and an update on current and potential uses in health care today. Information on the FDA-approved regimen and alternative protocols for management of mifepristone in its use in abortion care are presented.
2000年9月,美国食品药品监督管理局(FDA)批准将米非司酮用于药物流产。尽管米非司酮的研发和上市是因其具有实现孕早期药物流产的潜力,但它在医疗保健领域还有其他应用,包括治疗妇科疾病、癌症和库欣病。堕胎的争议性主导了有关米非司酮的宣传。米非司酮在药物流产中的安全性和有效性证据被掩盖,许多临床医生并不了解该药物的其他潜在用途。本文讨论了米非司酮的药理学背景信息、研发情况和研究进展,并介绍了其目前在医疗保健领域的现有及潜在用途。文中还提供了FDA批准的米非司酮用于流产护理的方案以及替代方案的相关信息。